drugset / Trial / NCT06207799
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
Timeline
- Start
- 2024-07-17
- Primary completion
- 2029-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Background | Busulfan | Small molecule | — | Oral |
| Background | G-CSF | Unknown | — | Intravenous |
| Background | Melphalan | Small molecule | — | Intravenous |
| Background | Plerixafor | Small molecule | — | Subcutaneous |